Welcome to our dedicated page for Affimed N.V. news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed N.V. stock.
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company headquartered in Mannheim, Germany, with additional offices in New York, NY. Affimed is dedicated to leveraging the power of the innate immune system to develop innovative immuno-oncology therapies primarily aimed at treating various cancers. The company is at the forefront of developing its proprietary innate cell engagers (ICE®), which are designed to target and eliminate both hematologic and solid tumors.
At the core of Affimed's innovation is their ROCK® platform, a state-of-the-art technology that generates customized ICE® molecules. These molecules harness the natural power of immune cells, such as natural killer (NK) cells and T-cells, to target and destroy cancer cells. Affimed's lead products include AFM13 (acimtamig), AFM24, and AFM28, which are currently undergoing various stages of clinical trials.
AFM13, the company's flagship innate cell engager, shows promise in treating CD30-positive hematologic tumors. It has demonstrated significant clinical efficacy in heavily pretreated patients with refractory Hodgkin lymphoma, achieving high objective response rates (ORR) and complete response (CR) rates. AFM13 is being investigated in combination with NK cells in the LuminICE-203 study, with initial data expected in the first half of 2024.
AFM24 is another key candidate, targeting EGFR-expressing solid tumors. It is currently being tested in combination with atezolizumab, a checkpoint inhibitor, in the AFM24-102 Phase 1/2a study. Recent data showed a disease control rate of 73.3% in heavily pretreated patients with EGFR wild-type non-small cell lung cancer (NSCLC), including significant objective responses. The FDA has granted Fast Track designation for this combination therapy, highlighting its potential to meet unmet medical needs.
AFM28 targets CD123-positive acute myeloid leukemia (AML). Preclinical studies have shown that AFM28 can effectively reduce tumor growth and eliminate leukemic blasts and stem cells. The drug is currently in early clinical development, with future plans to test it in combination with allogeneic off-the-shelf NK cells.
Affimed is also committed to strategic collaborations and partnerships to advance its clinical programs. Notable collaborations include those with Artiva Biotherapeutics, The University of Texas MD Anderson Cancer Center, and Roche. These partnerships are aimed at enhancing the efficacy and safety profiles of Affimed's therapies and bringing innovative treatments to patients more quickly.
Despite facing challenges such as restructuring and a reduction in workforce, Affimed remains focused on advancing its clinical pipeline. The company's strong leadership team, extensive experience in biotechnology and pharmaceuticals, and a clear mission to revolutionize cancer treatment underscore its commitment to giving patients back their innate ability to fight cancer.
For more information about Affimed's people, pipeline, and ongoing projects, please visit www.affimed.com.
Affimed has reported promising results from its phase 1/2 study of AFM13 combined with cord blood-derived NK cells in patients with CD30-positive Hodgkin and Non-Hodgkin lymphomas. Among 31 Hodgkin lymphoma patients, an impressive objective response rate (ORR) of 97% and a complete response (CR) rate of 77% were observed. Notably, all participants had failed previous treatments. The study showed a favorable safety profile, with no significant adverse events reported. Affimed continues to explore the market potential for AFM13, aiming to address unmet needs in this patient population.
Affimed N.V. (Nasdaq: AFMD) announced an investor event to review clinical data and development plans for AFM13 in CD30 expressing malignancies. This event will take place on December 10, 2022, at 4:00 p.m. CST during the 64th American Society of Hematology Annual Meeting in New Orleans. AFM13 has shown promising efficacy in Hodgkin Lymphoma and T cell lymphoma, with high response rates in both monotherapy and combination trials. Affimed recently partnered with Artiva to further develop AFM13 with NK cell therapies. A webcast of the event will be available for those unable to attend.
Affimed reported Q3 2022 results highlighting a revenue increase to €14.9 million, up from €8.7 million year-over-year, primarily from collaborations with Genentech and Roivant. The company has entered a partnership with Artiva Biotherapeutics to advance AFM13 for CD30-positive lymphomas. AFM13's combination therapy maintains a 100% overall response rate in trials. Operating cash usage was €19 million, with cash reserves at €222.9 million expected to last through mid-2024. The net loss for Q3 was €16.5 million, or €0.11 per share, showing slight improvement from the previous year.
Affimed N.V. (Nasdaq: AFMD) has announced promising results from two phase 1/2a trials involving AFM24, a bispecific innate cell engager targeting EGFR in patients with solid tumors. Findings indicate that AFM24 activates NK cells and shows initial signs of clinical activity when combined with atezolizumab, an immune checkpoint inhibitor, without dose-limiting toxicities. The data will be presented during the Society for Immunotherapy of Cancer (SITC) conference on November 10 and 11, 2022, with further updates available on Affimed’s website.
Affimed N.V. (Nasdaq: AFMD) will release its third quarter 2022 results and corporate update on November 15, 2022, followed by a conference call at 8:30 a.m. EST / 14:30 CET. Investors can join via phone or through a webcast available on the company’s website. The call features the latest updates on Affimed’s immuno-oncology initiatives and its ROCK® platform designed to combat various cancers by utilizing the innate immune system. A replay will be accessible for 30 days post-call.
Affimed and Artiva have announced a strategic partnership to develop a combination therapy targeting CD30-positive lymphoma patients. This collaboration will utilize Affimed's AFM13 and Artiva's AB-101, which has shown impressive response rates in clinical studies. The investigational new drug submission to the FDA is expected in the first half of 2023. Affimed will retain 67% of the revenue generated from the therapy, while Artiva will receive 33%. This partnership builds on two years of preclinical research and aims to expedite treatment for patients with significant unmet medical needs.
Affimed announced promising results from its ongoing phase 1/2 trial of AFM13 combined with allogeneic NK cells for CD30-positive lymphoma patients. Among 24 patients, the treatment achieved a 100% overall response rate and a 70.8% complete response rate. Patients tolerated the treatment well, receiving up to four cycles. Further details will be presented on December 10, 2022, during the ASH Annual Meeting. Additionally, preclinical data for AFM28 highlights its potential efficacy against CD123-positive leukemic cells, set to be presented on December 12, 2022.
Affimed N.V. (Nasdaq: AFMD) announced its CEO, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on November 16, 2022, at 12:55 p.m. GMT. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event. Affimed is a clinical-stage immuno-oncology firm focused on enhancing patients' immune responses against cancer through its innovative ROCK® platform. The company aims to utilize the innate immune system to combat various tumors, showcasing a strong commitment to cancer research.
Affimed N.V. (Nasdaq: AFMD) has announced the acceptance of two abstracts showcasing new data on their innate cell engager (ICE®) AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, scheduled for November 8-12, 2022. The first poster will detail findings from a phase 1 study of AFM24 monotherapy, while the second will present initial results from a phase 1 dose escalation study of AFM24 in combination with Roche’s atezolizumab. AFM24 targets EGFR-expressing solid tumors and is part of Affimed's innovative cancer treatment approach.
Affimed N.V. (Nasdaq: AFMD) announced the phase 1 data on its innate cell engager AFM24 at the ESMO Congress. The recommended phase 2 dose (RP2D) was set at 480 mg, with ongoing enrollment in specific disease cohorts. The trial observed stable disease in 10 of 27 evaluable patients, with some patients maintaining stable disease for over four months. The treatment was well tolerated, with no on-study deaths and no maximum tolerated dose reached. AFM24 activates both the innate and adaptive immune systems, marking a significant milestone for its development.
FAQ
What is the current stock price of Affimed N.V. (AFMD)?
What is the market cap of Affimed N.V. (AFMD)?
What does Affimed N.V. specialize in?
What is the ROCK® platform?
What are Affimed's key clinical candidates?
What is AFM13 used for?
What is the significance of AFM24's Fast Track designation?
How does AFM28 work?
What collaborations does Affimed have?
Where is Affimed N.V. headquartered?
What are the recent achievements of Affimed?
What is the company's mission?
